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were in the following order: PBS > SUPARTZ® > 1 injection
of Gel-200 ≥ 2 injections of Gel-200. Efficacy of Gel-200 for
suppression of cartilage degeneration was also demonstrated
by a reduction of the increase in chondroitin 6-sulfate (6S) in
the synovial fluid. In addition, Gel-200 appeared to improve the
symptoms of synovitis, as judged from the reduction in increase
of synovial fluid, protein and chondroitin 4-sulfate (4S) contents.
Overall, since cartilage degeneration is milder when synovitis
is not severe, these changes induced by Gel-200 may interact
beneficially to relieve the progression of pathological changes.
Histopathological findings of articular cartilage supported the
morphological assessment. In the histopathological examination
of synovium, cuboidal/stratified synovial epithelium, subepithe-
lial cellular infiltration, subepithelial fibrosis/edema, subepithelial
hemorrhage and subepithelial calcium deposition were observed
in all the experimental groups. These changes were less severe
in Gel-200 groups compared to those in the control group.
Conclusions: These data show that in a rabbit ACL transection
model of OA, a single intra-articular injection of Gel-200 was
superior to five injections of SUPARTZ® in slowing cartilage
degeneration. It is considered that this superiority of Gel-200 is
attributed to its highly cross-linked structure.
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THE IN VIVO ACTIVATION OF PPARγ BY THE LIGAND
PIOGLITAZONE REDUCES THE DEVELOPMENT OF
CARTILAGE LESIONS AND SYNTHESIS OF CATABOLIC
FACTORS IN AN OSTEOARTHRITIS DOG MODEL
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M. Boily, J.-P. Pelletier
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Purpose: The peroxisome proliferator-activated receptor
(PPAR)γ is a known modulator of a number of inflammatory
pathways. Emerging evidence indicates that PPARγ may have
protective effects on structural changes in osteoarthritis (OA). In
this study we evaluated the in vivo therapeutic effect of a PPARγ
agonist, pioglitazone, on the development of structural lesions in
a dog anterior cruciate ligament (ACL) model of OA and explored
the effect of the drug on the major synthetic pathways involved
in the disease process.
Methods: OA was surgically induced in 24 dogs. The OA dogs
were randomly divided into 3 groups (n=8 per group) and treated
orally with either placebo, 15 mg/kg/day of pioglitazone, or 30
mg/kg/day of pioglitazone. The treatment began the day after
surgery and continued for a period of 8 weeks. The severity of
cartilage lesions was scored macroscopically. Cartilage speci-
mens from femoral condyles and tibial plateaus were processed
for histologic evaluation. Both cartilage and synovial membrane
were processed for quantitative RT-PCR and immunohistochem-
istry. Specific probes and antibodies were used to study iNOS,
MMP-1 and ADAMTS-5.
Results: Pioglitazone treatment reduced the development of
cartilage lesions in a dose-dependent manner. There was a
reduction in the lesion scores, and statistical significance was
reached for the medial condyle; p<0.04 and 0.03 respectively for
15 and 30 mg/kg/day of pioglitazone. This decrease correlated
with the cartilage histologic scores. Pioglitazone also significantly
reduced the production of OA key mediators, iNOS, MMP-1 and
ADAMTS-5 in cartilage.
Conclusions: This study demonstrated the efficacy of pioglita-
zone, a PPARγ agonist, at reducing articular lesions in a dog
model of OA. These results provide a new possibility for thera-
peutic intervention in OA, in which in vivo activation of PPARγ
inhibits major cartilage catabolic factors responsible for articular
tissue degradation.
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RABBITS
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Purpose: To investigate and compare the characteristics of the
reconstructed articular surface microscopically and histologically
after a time period of 6 weeks following the treatment of a focal
defect of the right femoral head with subchondral drilling and
autologous osteochondral transplantation in rabbits
Methods: A 2,5 mm diameter and 3 mm depth iatrogenic os-
teochondral defect in the anterolateral weight bearing area of
the right femoral head was created in 12 rabbits. In a group of
6 rabbits the lesion was treated with autologous osteochondral
transplantation. The donor site for the transplant was the lat-
eral condyle of the ipsilateral knee joint. The other group of 6
rabbits was treated with subchondral drilling. Both groups were
sacrificed after a time period of 6 weeks and specimens were
evaluated histologically under the classification system of the
ICRS. For statistical analysis we used the Mann - Wittney test
Results: According to the ICRS score statistical significance was
found for all variables between the 2 groups (subchondral drilling
6 weeks vs autologous osteochondral transplantation 6 weeks):
articular surface (p=0,049), matrix (p=0,003), cell distribution (p<
0,0005), subchondral bone (p=0,010), cartilage mineralization
(p=0,0) except cell population viability.
Conclusions: In cases of focal osteochondral defect of the
femoral head in rabbits, reconstruction of the articular surface
through autologous osteochondral graft transplantation gives su-
perior macroscopical and histological results in comparison to
subchondral drilling
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Purpose: Interleukin-1 (IL-1) is thought to play a role in both
the joint destruction seen in osteoarthritis (OA) and the pain that
develops with the disease. The monoiodoacetate (MIA) model of
osteoarthritis in the rat has been used as a model of OA pain
and additionally, displays gross pathology and histologic changes
that resemble some components of OA pathology. This study
therefore uses the MIA model to examine the effect of the IL-1
receptor antagonist (IL-1RA) Anakinra on cartilage degradation
and joint pain.
Methods: 20 male Lewis rats of 7 weeks of age were randomized
into 2 experimental groups of n=10. The rats were then implanted
with Alzet osmotic pumps (model 2ML) containing either vehicle
(PBS) or IL-1RA at a dose of 90mg/kg per day. Three days
after osmotic pump implantation the right knees of each rat
were injected with 0.3mg of MIA in 50ul of saline and the
left knees with 50ul of saline. 6 rats from each group were
then measured for pain on days 1, 2, 3,8,10 and 14 post MIA
injection by incapacitance testing. This measures the difference
in paw weight bearing between the MIA and saline injected
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knees and for this study each measurement was the average of
three separate measurements measured over 1 second. On day
15 the animals were euthanized and the right knees dissected
out, disarticulated and the tibial plateaus photographed. The
images were then divided into 4 regions, medial anterior and
posterior, lateral anterior and posterior and each region scored
for pathology by 5 blinded observers using a 0 to 6 scale. The
total score for each joint was then calculated. Both the pain
and pathology results were analyzed using a student’s t-test to
compare the results from the two experimental groups.
Results: Pain - On each day that pain was measured the
difference in weight bearing between the MIA and saline injected
knees was significantly less in the rats dosed with Anakinara
compared to those dosed with vehicle (p<0.001). This difference
in weight bearing resulted in approximately a 50% reduction in
the pain response in Anakinara dosed rats compared to those
dosed with vehicle.
Gross Pathology: In contrast to the pain results Anakinara had
no effect in reducing the cartilage degradation seen in the MIA
model. The average joint score for both groups was 2.69.
Conclusions: The IL-1RA antagonist was able to significantly
reduce the pain measured in the MIA model but had no effect on
the cartilage degradation seen in this model.
P70
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Purpose: The aim of this study was to evaluate the effects of
Glucosamine (GlcN) and its N-acetyl phenylalanine derivative
(NAPA), in rabbits with experimental Osteoarthritis (OA).
Methods: Experimental OA was induced by two intra-articular
injections of vitamin A (Vit A) in rabbit knees. A severe OA without
exposure of subchondral bone was obtained 35 days after the
first injection. Then, rabbit OA left knees were intra-articularly
injected with 2.5 mM GlcN or 2.5 mM NAPA, right knees were
left untreated as OA control. Animals intra-articularly injected
with normal saline solution were used as healthy control. Rabbits
were sacrificed 70 days following first Vit A administration for
histological assessment (May Grunwald-Giemsa, Hematoxylin-
Eosin and Alcian Blue staining) and molecular analysis (Real
Time-PCR) of the knee joints. Cathepsin B enzymatic activity
was analyzed in rabbit primary chondrocytes.
Results: Histological sections obtained from articular cartilage
showed a major cellularity, a better tissue organization and a
major presence of matrix components in NAPA-treated samples
and to a lesser extent in GlcN-treated samples compared to
cartilage sections from OA knees.
Molecular analysis of mRNA expression levels of several genes
coding for matrix components and remodeling enzymes in OA
samples showed a lower expression compared to healthy tissues.
Whereas GlcN and NAPA-treated samples showed a restored
expression levels compared to OA cartilage, fairly close to values
found in healthy animals.
Previously, we reported an inhibitory effect of GlcN and NAPA
on Cathepsin B enzymatic activity in vitro assay. In order to
analyze the effects of GlcN and NAPA on Cathepsin B in vivo,
we isolated rabbit primary chondrocytes from healthy cartilage.
First passage culture chondrocytes were left untreated, treated
with TNFα, with TNFα plus GlcN and with TNFα plus NAPA.
Cathepsin B enzymatic activity resulted inhibited by NAPA and
to a lesser extent by GlcN.
Conclusions: The double effect exerted by GlcN and NAPA,
improved expression level of genes involved in cartilage home-
ostasis and inhibitory effect on Cathepsin B enzymatic activity,
may explain the cartilage repair observed by histological analysis
of OA joints treated with GlcN and NAPA.
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Purpose: Failure to develop therapies for osteoarthritis patients
suggests that the degenerative changes in the joint are prob-
ably no longer sensitive to treatment. It is therefore important
that early diagnosis of osteoarthritis becomes available when
treatment can still halt or even reverse the joint destruction. Our
goal was to develop a guinea pig model with only mild forms
of osteoarthritis that could serve as a model for early human
osteoarthritis to discover early osteoarthritis biomarkers and to
test new treatments that are aimed at intervention early in the
disease process.
Methods: Osteoarthritis was induced by bilateral transection
of the medial meniscus in Dunkin-Hartley guinea pigs using a
surgical procedure that was minimally invasive to avoid cartilage
damage due to inflammation and/or intra-articular bleeding. At
4, 8, and 12 weeks after surgery the severity of osteoarthritis
was macroscopically and histologically assessed and serum and
urinary biomarkers were measured. The effect of daily treatment
with 0.15 mg/kg Risedronate, 20 mg/kg Pioglitazone, 5 mg/kg
Anakinra, and 0.5 mg/kg Galardin was evaluated in a 12-week
study design.
Results: Four weeks after meniscal transection small lesions in
the cartilage were macroscopically observed at the medial side
of the joint, starting at the femoral head and the central part
of the tibial plateau. Clear, but mild progression of osteoarthritis
was detectable over time. However, 12 weeks after surgery the
lesions were still restricted to the medial side of the joint and did
not reach into the subchondral bone. Mild signs of osteoarthritis,
but significantly less than in the meniscal transection group,
were observed in the control and sham groups as well due to
the susceptibility of the strain to the spontaneous development
of osteoarthritis. Increased cartilage destruction in the meniscal
transection group was also histologically observed.
Of the urinary biomarkers tested, only CTX-II was significantly
increased in the meniscal transection group, but only at week 8.
No increase in urinary HP/LP ratio (a measure for the relative
turnover of cartilage over bone metabolism) nor in serum COMP
levels was observed in the meniscal transection group within 12
weeks after surgery.
Strategies for treatment were chosen such that different pro-
cesses in osteoarthritis development were targeted: bone de-
struction (Risedronate), inflammation (Pioglitazone and Anakin-
ra), and cartilage destruction (Galardin). Unfortunately, none of
these treatments showed beneficial effects on the macroscopic
score in the meniscal transection model.
Conclusions: Mild joint destruction was observed in the first 12
weeks after bilateral meniscal transection. However, these early
degenerative changes in the cartilage could not be detected
by classic biomarkers. Probably, the cartilage destruction is still
too mild to be measured in the systemic circulation. Further re-
search into new biomarkers is needed to detect and monitor the
early stages of osteoarthritis. Proteomics and metabolomics hold
promise for the future to find such biomarkers. Previously, an uri-
